Cargando…

The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji

BACKGROUND: In 2012, Fiji introduced the 10-valent pneumococcal conjugate vaccine (PCV10). We assessed the impact of PCV10 on invasive pneumococcal disease (IPD), probable bacterial or pneumococcal meningitis (PBPM), meningitis and sepsis 3-5 years post-introduction. METHODS: Laboratory-confirmed IP...

Descripción completa

Detalles Bibliográficos
Autores principales: Reyburn, R., Tuivaga, E.J., Ratu, F.T., Dunne, E.M., Nand, D., Kado, J., Jenkins, K., Tikoduadua, L., Jenney, A., Howden, B.P., Ballard, S.A., Fox, K., Devi, R., Satzke, C., Rafai, E., Kama, M., Flasche, S., Mulholland, E.K., Russell, F.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741523/
https://www.ncbi.nlm.nih.gov/pubmed/35028629
http://dx.doi.org/10.1016/j.lanwpc.2021.100352
_version_ 1784629510330646528
author Reyburn, R.
Tuivaga, E.J.
Ratu, F.T.
Dunne, E.M.
Nand, D.
Kado, J.
Jenkins, K.
Tikoduadua, L.
Jenney, A.
Howden, B.P.
Ballard, S.A.
Fox, K.
Devi, R.
Satzke, C.
Rafai, E.
Kama, M.
Flasche, S.
Mulholland, E.K.
Russell, F.M.
author_facet Reyburn, R.
Tuivaga, E.J.
Ratu, F.T.
Dunne, E.M.
Nand, D.
Kado, J.
Jenkins, K.
Tikoduadua, L.
Jenney, A.
Howden, B.P.
Ballard, S.A.
Fox, K.
Devi, R.
Satzke, C.
Rafai, E.
Kama, M.
Flasche, S.
Mulholland, E.K.
Russell, F.M.
author_sort Reyburn, R.
collection PubMed
description BACKGROUND: In 2012, Fiji introduced the 10-valent pneumococcal conjugate vaccine (PCV10). We assessed the impact of PCV10 on invasive pneumococcal disease (IPD), probable bacterial or pneumococcal meningitis (PBPM), meningitis and sepsis 3-5 years post-introduction. METHODS: Laboratory-confirmed IPD and PBPM cases were extracted from national laboratory records. ICD-10-AM coded all-cause meningitis and sepsis cases were extracted from national hospitalisation records. Incidence rate ratios were used to compare outcomes pre/post-PCV10, stratified by age groups: 1-23m, 2-4y, 5-9y, 10-19y, 20-54y, ≥55y. To account for different detection and serotyping methods in the pre-and post-PCV10 period, a Bayesian inference model estimated serotype-specific changes in IPD, using pneumococcal carriage and surveillance data. FINDINGS: There were 423 IPD, 1,029 PBPM, 1,391 all-cause meningitis and 7,611 all-cause sepsis cases. Five years post-PCV10 introduction, IPD declined by 60% (95%CI: 37%, 76%) in children 1-23m months old, and in age groups 2-4y, 5-9y, 10-19y although confidence intervals spanned zero. PBPM declined by 36% (95%CI: 21%, 48%) among children 1-23 months old, and in all other age groups, although some confidence intervals spanned zero. Among children <5y of age, PCV10-type IPD declined by 83% (95%CI; 70%, 90%) and with no evidence of change in non-PCV10-type IPD (9%, 95%CI; -69, 43%). There was no change in all-cause meningitis or sepsis. Post-PCV10, the most common serotypes in vaccine age-eligible and non-age eligible people were serotypes 8 and 23B, and 3 and 7F, respectively. INTERPRETATIONS: Our study demonstrates the effectiveness of PCV10 against IPD in a country in the Asia-Pacific of which there is a paucity of data. FUNDING: This study was support by the Department of Foreign Affairs and Trade of the Australian Government and Fiji Health Sector Support Program (FHSSP). FHSSP is implemented by Abt JTA on behalf of the Australian Government.
format Online
Article
Text
id pubmed-8741523
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-87415232022-01-12 The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji Reyburn, R. Tuivaga, E.J. Ratu, F.T. Dunne, E.M. Nand, D. Kado, J. Jenkins, K. Tikoduadua, L. Jenney, A. Howden, B.P. Ballard, S.A. Fox, K. Devi, R. Satzke, C. Rafai, E. Kama, M. Flasche, S. Mulholland, E.K. Russell, F.M. Lancet Reg Health West Pac Article BACKGROUND: In 2012, Fiji introduced the 10-valent pneumococcal conjugate vaccine (PCV10). We assessed the impact of PCV10 on invasive pneumococcal disease (IPD), probable bacterial or pneumococcal meningitis (PBPM), meningitis and sepsis 3-5 years post-introduction. METHODS: Laboratory-confirmed IPD and PBPM cases were extracted from national laboratory records. ICD-10-AM coded all-cause meningitis and sepsis cases were extracted from national hospitalisation records. Incidence rate ratios were used to compare outcomes pre/post-PCV10, stratified by age groups: 1-23m, 2-4y, 5-9y, 10-19y, 20-54y, ≥55y. To account for different detection and serotyping methods in the pre-and post-PCV10 period, a Bayesian inference model estimated serotype-specific changes in IPD, using pneumococcal carriage and surveillance data. FINDINGS: There were 423 IPD, 1,029 PBPM, 1,391 all-cause meningitis and 7,611 all-cause sepsis cases. Five years post-PCV10 introduction, IPD declined by 60% (95%CI: 37%, 76%) in children 1-23m months old, and in age groups 2-4y, 5-9y, 10-19y although confidence intervals spanned zero. PBPM declined by 36% (95%CI: 21%, 48%) among children 1-23 months old, and in all other age groups, although some confidence intervals spanned zero. Among children <5y of age, PCV10-type IPD declined by 83% (95%CI; 70%, 90%) and with no evidence of change in non-PCV10-type IPD (9%, 95%CI; -69, 43%). There was no change in all-cause meningitis or sepsis. Post-PCV10, the most common serotypes in vaccine age-eligible and non-age eligible people were serotypes 8 and 23B, and 3 and 7F, respectively. INTERPRETATIONS: Our study demonstrates the effectiveness of PCV10 against IPD in a country in the Asia-Pacific of which there is a paucity of data. FUNDING: This study was support by the Department of Foreign Affairs and Trade of the Australian Government and Fiji Health Sector Support Program (FHSSP). FHSSP is implemented by Abt JTA on behalf of the Australian Government. Elsevier 2022-01-05 /pmc/articles/PMC8741523/ /pubmed/35028629 http://dx.doi.org/10.1016/j.lanwpc.2021.100352 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Reyburn, R.
Tuivaga, E.J.
Ratu, F.T.
Dunne, E.M.
Nand, D.
Kado, J.
Jenkins, K.
Tikoduadua, L.
Jenney, A.
Howden, B.P.
Ballard, S.A.
Fox, K.
Devi, R.
Satzke, C.
Rafai, E.
Kama, M.
Flasche, S.
Mulholland, E.K.
Russell, F.M.
The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji
title The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji
title_full The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji
title_fullStr The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji
title_full_unstemmed The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji
title_short The impact of 10-valent pneumococcal vaccine introduction on invasive disease in Fiji
title_sort impact of 10-valent pneumococcal vaccine introduction on invasive disease in fiji
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741523/
https://www.ncbi.nlm.nih.gov/pubmed/35028629
http://dx.doi.org/10.1016/j.lanwpc.2021.100352
work_keys_str_mv AT reyburnr theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT tuivagaej theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT ratuft theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT dunneem theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT nandd theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT kadoj theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT jenkinsk theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT tikoduadual theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT jenneya theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT howdenbp theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT ballardsa theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT foxk theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT devir theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT satzkec theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT rafaie theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT kamam theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT flasches theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT mulhollandek theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT russellfm theimpactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT reyburnr impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT tuivagaej impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT ratuft impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT dunneem impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT nandd impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT kadoj impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT jenkinsk impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT tikoduadual impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT jenneya impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT howdenbp impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT ballardsa impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT foxk impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT devir impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT satzkec impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT rafaie impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT kamam impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT flasches impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT mulhollandek impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji
AT russellfm impactof10valentpneumococcalvaccineintroductiononinvasivediseaseinfiji